Genmab A/S (NASDAQ:GMAB) Price Target Raised to $70.00

Genmab A/S (NASDAQ:GMAB) had its target price raised by HC Wainwright from $50.00 to $70.00 in a research report report published on Thursday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Genmab A/S’s Q4 2026 earnings at $0.46 EPS, Q1 2027 earnings at $0.35 EPS, Q2 2027 earnings at $0.59 EPS, Q3 2027 earnings at $0.61 EPS and Q4 2027 earnings at $0.61 EPS.

GMAB has been the subject of several other reports. New Street Research set a $43.00 price objective on Genmab A/S in a research report on Wednesday, July 22nd. Guggenheim lifted their target price on Genmab A/S from $45.00 to $54.00 and gave the company a “buy” rating in a research report on Monday, October 5th. JPMorgan Chase & Co. upgraded Genmab A/S from a “neutral” rating to an “overweight” rating in a research note on Monday, October 26th. TD Cowen upped their price target on Genmab A/S from $43.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday, October 26th. Finally, Truist Financial upped their price target on Genmab A/S from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.61.

Genmab A/S Stock Up 1.0%

Shares of GMAB stock opened at $57.06 on Thursday. The firm has a fifty day moving average of $37.12 and a 200-day moving average of $30.58. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81. Genmab A/S has a 12-month low of $23.62 and a 12-month high of $59.97. The company has a market capitalization of $35.61 billion, a price-to-earnings ratio of 44.93, a P/E/G ratio of 2.28 and a beta of 0.81.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.12 billion. As a group, equities research analysts predict that Genmab A/S will post 1.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

Large investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Genmab A/S in the 3rd quarter valued at about $177,000. Vise Technologies Inc. lifted its stake in Genmab A/S by 41.6% in the 3rd quarter. Vise Technologies Inc. now owns 23,186 shares of the company’s stock valued at $827,000 after purchasing an additional 6,809 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Genmab A/S by 46.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 17,692 shares of the company’s stock worth $629,000 after purchasing an additional 5,615 shares during the period. Park Avenue Securities LLC grew its holdings in Genmab A/S by 2.4% during the third quarter. Park Avenue Securities LLC now owns 11,258 shares of the company’s stock worth $402,000 after purchasing an additional 265 shares during the period. Finally, Signaturefd LLC grew its holdings in Genmab A/S by 8.5% during the third quarter. Signaturefd LLC now owns 17,842 shares of the company’s stock worth $636,000 after purchasing an additional 1,400 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Genmab A/S

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Genmab reported that its cancer drug reduced the risk of death by 50% in a head-and-neck cancer trial and met the study’s primary goals. The results could strengthen the drug’s commercial prospects and support potential changes to treatment standards. Genmab drug cuts death risk 50% in head and neck cancer trial
• Positive Sentiment: Analysts raised their valuation expectations: Guggenheim increased its price target to $80 from $58 and maintained a Buy rating; Morgan Stanley raised its target to $57 from $42 while retaining an Equal Weight rating; and Goldman Sachs initiated or reiterated a Buy recommendation. Guggenheim analyst recommendation Genmab receives a Buy from Goldman Sachs
• Positive Sentiment: Truist reaffirmed its Buy rating and lifted its target to $67 from $45, while HC Wainwright raised its target to $70 from $50. HC Wainwright also maintained a Buy rating, suggesting analysts see additional upside despite the recent rally. HC Wainwright analyst recommendation
• Positive Sentiment: Coverage describing Genmab as potentially undervalued after its trial successes adds to the bullish narrative around the company’s pipeline and long-term growth prospects. Can Genmab still be undervalued after its trial wins?

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab’s marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.